Bionaut will provide a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel pathway reporter system to validate new compounds. AnalytiCon will apply its natural product and medicinal chemistry expertise to optimize the activity and selectivity of these compounds for further preclinical development by Bionaut.
Bionaut has applied its Sentinel system to selectively measure the activity of cellular signaling pathways in cancer cells and identified compounds, including BNC4, which specifically inhibit the ability of cancer cells to grow under stress conditions in a variety of in vitro studies.
“We are delighted to have the chemistry team at AnalytiCon developing novel analogues for our lead program in cancer,” said Thomas Klein, COO of Bionaut. “We believe their unique combination of expertise in natural products and analog medicinal chemistry will provide the fastest route to identify novel drug candidates to take forward towards human clinical studies.”